Neuroinflammation, the chronic activation of the brain’s immune system, is now recognized as a central player in devastating conditions such as Alzheimer’s and Parkinson’s disease. When microglia encounter threats like lipopolysaccharide (LPS), a bacterial toxin commonly used in the laboratory to provoke inflammation, they transform from slender, branched sentinels into amoeboid, angry cells that pump out interleukin-6, interleukin-1 beta, tumor necrosis factor-alpha and nitric oxide. In moderation this response is protective; in excess it damages synapses and kills neurons. Finding drugs that dial this response down, without shutting off the immune system entirely, has become a major goal of neuropharmacology.

Cardamonin has attracted attention because it is abundant, inexpensive, and has a long history of safe use in traditional medicine. Earlier animal work showed that it could ease cognitive impairment in Alzheimer’s-model mice, protect the brain after stroke-like injury, and promote recovery after nerve damage. But the precise molecular switches it flips inside microglia remained murky. To pin them down, a team led by Jingjing Lu and Lijun Cui of Huzhou Third Municipal Hospital turned to network pharmacology, a computational strategy that maps all the possible protein targets of a compound and the biological pathways they share with a disease.

The computational screen was strikingly productive. By merging predicted cardamonin targets from three databases with genes linked to neurodegenerative disease, the researchers narrowed in on 137 overlapping targets and eventually 11 hub proteins sitting at the center of the interaction network. These included the epidermal growth factor receptor (EGFR), the survival kinase AKT1, the chaperone HSP90AB1, the inflammatory enzyme COX-2, and NF-kappaB p65, a master transcription factor for inflammatory genes. Pathway analysis pointed repeatedly to three connected signaling cascades: EGFR/PI3K/AKT1, the MAPK/ERK cascade, and NF-kappaB signaling.

Molecular docking added computational weight to the idea. When the researchers floated the cardamonin molecule into the three-dimensional structures of these target proteins, all binding energies came out below the minus 5 kilocalorie per mole threshold typically used to flag plausible interactions, with the strongest predicted binding to AKT1 at minus 8.6 kilocalories per mole and to EGFR at minus 8.2. Docking cannot prove that a drug binds a protein in a living cell, but it gave the team a concrete hypothesis to test at the bench.

The crucial experiments used BV2 microglial cells, a widely studied mouse microglial line, stimulated with LPS. Pretreating the cells with cardamonin at concentrations between 4 and 16 micromolar, levels that did not harm the cells themselves, dramatically blunted the inflammatory barrage. Levels of IL-6, IL-1 beta, TNF-alpha and nitric oxide in the culture fluid fell significantly, and the messenger RNA and protein output of the inflammatory enzymes iNOS and COX-2 dropped in parallel. Under the microscope, the compound also pushed the LPS-distorted microglia back toward their resting, branched shape.

Western blotting revealed the mechanism in molecular detail. LPS normally drives the phosphorylation, the chemical activation, of EGFR, PI3K, AKT1 and ERK1/2, and triggers the nuclear translocation of NF-kappaB p65, the step that lets the transcription factor switch on inflammatory genes. Cardamonin pretreatment reversed all of these events. Critically, when the researchers blocked EGFR or PI3K with the inhibitors AG-1478 or LY294002, the drugs reproduced cardamonin’s effects, and combining the compound with either inhibitor produced no additional benefit. That pattern strongly suggests cardamonin acts along this same signaling axis rather than through a separate route.

The compound also tamed the oxidative side of the inflammatory storm. Activated microglia generate reactive oxygen species that punch holes in mitochondrial membranes, and cardamonin dose-dependently reduced this ROS accumulation while preserving the mitochondrial membrane potential measured with the JC-1 fluorescent probe. Because mitochondrial damage is a trigger for cellular suicide, this result hinted that calming microglia might also spare neighboring neurons from apoptotic death.

To test that idea directly, the team collected the liquid medium, the conditioned medium, from each treated microglial culture and applied it to SH-SY5Y human neuronal cells. Medium from LPS-activated microglia slashed neuronal viability, distorted cell bodies, withered neurites, and cranked up both TUNEL-positive apoptosis and cleaved caspase-3, the executioner enzyme of programmed cell death. Medium from microglia that had received cardamonin before LPS was far less toxic, preserving neuronal survival and morphology. Importantly, cardamonin applied directly to the neurons had no protective effect, confirming that the benefit flows entirely through the immune cells rather than the neurons themselves.

The authors are careful about the limits of the work. The findings rest on immortalized cell lines rather than primary microglia and neurons, the cross-species co-culture model simplifies the real brain environment, and the anti-neuroinflammatory effects have not yet been confirmed in animals within this study. Oral bioavailability of cardamonin is also known to be limited, although prior mouse work suggests in vivo benefits may arise through indirect immune modulation rather than high brain exposure. Even so, by converging computational prediction, molecular docking and mechanistic cell biology on a single signaling axis, the study offers a coherent blueprint for how a humble plant chalcone might one day be developed into a multi-target therapy for inflammation-driven neurodegeneration.

Subject of Research: Neuroprotective and anti-neuroinflammatory mechanisms of cardamonin in microglia-neuron co-culture via the EGFR/PI3K/AKT1/ERK/NF-kappaB pathway

Article Title: Cardamonin attenuates SH-SY5Y neuronal apoptosis induced by LPS-activated microglia via modulation of the EGFR/PI3K/AKT1/ERK/NF-κB pathway

Article References: Lu, J., Zhou, R., Tang, K., Wang, H., Shen, Z., Huang, C., & Cui, L. (2026). Cardamonin attenuates SH-SY5Y neuronal apoptosis induced by LPS-activated microglia via modulation of the EGFR/PI3K/AKT1/ERK/NF-κB pathway. Frontiers in Pharmacology, 17, Article 1832453. https://doi.org/10.3389/fphar.2026.1832453

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1832453

Keywords: cardamonin, neuroinflammation, microglia, BV2 cells, SH-SY5Y neurons, EGFR/PI3K/AKT1 signaling, NF-kappaB, ERK1/2, network pharmacology, neurodegenerative diseases, oxidative stress, apoptosis

The significance of the work lies partly in what it did not do. Most previous investigations of bioactive compounds from P. martensii, a commercially vital aquaculture species farmed along the coasts of southern China and southwestern Japan, have relied on enzymatic hydrolysis, in which trypsin, alcalase, or flavourzyme chop discarded oyster flesh into short peptides with antioxidant or anti-inflammatory activity. Enzymatic digestion substantially reshapes the native molecular profile and risks destroying sensitive bioactive sequences. The new study instead collected roughly one liter of fresh mucus from 100 oysters during routine shucking, diluted it with ultrapure water, homogenized it at 4 degrees Celsius, centrifuged the mixture, filtered it through 0.45 and 0.22 micrometer membranes, and passed the filtrate through a 3 kilodalton molecular-weight-cutoff membrane. The low-molecular-weight permeate was then freeze-dried. This hydrolysis-free workflow preserves the mucus’s native cocktail of free amino acids, small peptides, nucleosides, and polar metabolites exactly as the oyster secretes them.

Chemical profiling revealed a composition dominated by small, water-soluble osmolytes. Targeted quantification showed that taurine accounted for 8.0 percent of the dry weight and betaine for 4.1 percent, while total amino acids measured after acid hydrolysis reached 6.0 percent. Inorganic components, chiefly chloride and sodium followed by sulfate, bicarbonate, potassium, and magnesium, made up 72.0 percent of the dry mass, and total sugars were minimal at 0.15 percent. Glycine was the predominant amino acid, followed by glutamic acid, proline, alanine, and valine. Untargeted liquid chromatography-mass spectrometry, performed under two orthogonal separation modes, reversed-phase C18 and hydrophilic interaction chromatography, generated distinct chemical fingerprints in which taurine and betaine appeared prominently under both conditions, and a feature putatively assigned to hypoxanthine emerged only under the HILIC mode. Because authentic standards were not run under identical chromatographic conditions, the authors treated these annotations as putative, a methodological caution that underscores how much of the extract’s chemistry remains uncharacterized.

With the extract characterized, the team turned to cellular models. In L929 murine fibroblasts, the workhorse cell type of connective tissue research, a single UVA dose of 10 joules per square centimeter, delivered at a peak wavelength of 365 nanometers, drove the cells into a senescent state. Prior toxicity testing across concentrations from 7.81 to 1,000 micrograms per milliliter had confirmed that AKN alone was non-cytotoxic, maintaining viability above 95 percent. When AKN was administered 12 hours before irradiation at 400 micrograms per milliliter, it significantly suppressed the mRNA levels of p16, p21, and p53, the canonical cell-cycle arrest genes whose upregulation marks premature cellular senescence. Senescence-associated beta-galactosidase staining, the gold-standard histochemical marker of the senescent phenotype, corroborated the molecular data: UVA-irradiated fibroblasts displayed the characteristic enlarged, flattened morphology and a pronounced increase in blue-stained cells, while AKN treatment markedly reduced the proportion of senescence-positive cells and largely restored normal morphology.

The extract also showed anti-inflammatory capacity in a second cellular model. BV2 murine microglial cells stimulated with lipopolysaccharide, a bacterial endotoxin that activates toll-like receptor 4-dependent inflammatory signaling, responded to AKN co-treatment with significantly reduced mRNA expression of the pro-inflammatory cytokines TNF-alpha, IL-6, and IL-1beta. AKN simultaneously lowered intracellular reactive oxygen species, measured by DCFH-DA fluorescence. This dual action on oxidative and inflammatory axes is mechanistically coherent with current models of photoaging, in which UVA-generated reactive oxygen species overwhelm endogenous antioxidant defenses, activate the nuclear factor-kappaB axis, and trigger a self-reinforcing feed-forward cascade linking oxidative stress, inflammatory signaling, the senescence-associated secretory phenotype, and irreversible cell-cycle arrest.

The decisive test came in living animals. Six- to seven-week-old male BALB/c mice were randomly assigned to five groups of six animals each: an untreated control, a UVA model group, and three treatment groups receiving topical applications of 1 milligram per milliliter AKN, 4 milligrams per milliliter AKN, or 4 milligrams per milliliter ergothioneine. Thirty minutes before each irradiation session, 200 microliters of the corresponding solution were applied to shaved dorsal skin, and the mice were exposed to UVA at 400 millijoules per square centimeter per session for 16 days, with investigators blinded to treatment allocation. By the end of the experiment, the UVA model group had developed the classic macroscopic photoaging phenotype: pronounced wrinkles, rough and dull skin texture, and loss of elasticity. Topical AKN visibly improved skin appearance in a dose-dependent manner, and at 4 milligrams per milliliter the dorsal skin closely resembled that of the non-irradiated control, performing alongside the ergothioneine reference.

Gene expression analysis of mouse dorsal skin reproduced the transcriptional signature of photoaged tissue. UVA irradiation upregulated p16, p21, p53, the matrix metalloproteinase gene Mmp9, and the inflammatory gene iNOS, while downregulating Col1a1, the gene encoding the alpha 1 chain of type I collagen, the principal structural protein of the dermal extracellular matrix. Treatment with 1 milligram per milliliter AKN significantly decreased p16, p21, p53, and iNOS mRNA levels, while 4 milligrams per millilliter AKN further suppressed Mmp9 and restored Col1a1 transcription. Western blot analysis confirmed that these changes translated to the protein level: the UVA model group showed elevated iNOS, phosphorylated p65, the activated subunit of the NF-kappaB inflammatory axis, and p16, and 4 milligrams per milliliter AKN significantly reduced all three markers.

Histological examination completed the picture. Hematoxylin-eosin staining revealed that chronic UVA exposure thickened the epidermis and disorganized the dermal architecture, while Masson’s trichrome staining showed a striking depletion of collagen fibers, visualized as reduced blue-stained density. These alterations recapitulate the well-documented histopathology of UVA-induced photoaging, in which chronic exposure drives epidermal hyperproliferation and dermal extracellular matrix degradation. AKN treatment mitigated the damage dose-dependently: 1 milligram per milliliter produced partial reductions in epidermal thickness and modest collagen recovery, while 4 milligrams per milliliter yielded a more pronounced epidermal thinning, a more organized dermis, and a substantial restoration of collagen deposition, confirmed by quantitative image analysis of epidermal thickness and collagen fiber density.

One of the study’s most intriguing findings concerns the comparison with the positive control. While ergothioneine significantly attenuated senescence and inflammatory markers, its regulation of Mmp9 and Col1a1 did not reach statistical significance, whereas 4 milligrams per milliliter AKN suppressed Mmp9 and increased Col1a1. The authors argue that AKN’s potency should not be read as a simple additive effect of its identified constituents. Rather, the unhydrolyzed extract functions as an integrated multi-component cluster in which taurine, betaine, free amino acids, native oligopeptide sequences, and a diverse pool of uncharacterized low-molecular-weight trace constituents act in concert, an entourage or synergistic matrix effect that simultaneously engages complementary defense pathways and reinforces extracellular matrix integrity. Preserving this native network, they contend, avoids the disruption of delicate bioactive synergies that frequently occurs during harsh fractionation, conferring protection that transcends the capabilities of isolated single compounds.

The findings arrive against a backdrop of substantial industrial by-product generation. Annual marine pearl harvests in East Asia reach tens of metric tons, and the industry concurrently produces thousands of metric tons of oyster soft-tissue biomass and mucosal secretions each year, most of which are discarded. Valorizing mucus as a source of photoprotective agents would convert a waste stream into a raw material for functional cosmetics, using a green processing workflow that avoids proteolytic enzymes, organic solvents, and laborious multi-step purification. The high abundance of low-molecular-weight, water-soluble constituents offers distinct formulation advantages for topical dermatological preparations. The authors acknowledge, however, that significant questions remain before translation: the precise active constituents and their synergistic interactions have not been resolved, cellular uptake and intracellular disposition of AKN components were not tracked, evaluations under chronic low-dose or combined UVA/UVB challenge are needed, and rigorous safety testing, including sensitization, repeated-dose toxicity, formulation stability, and human clinical trials, will be required before any cosmeceutical application. For now, the study establishes a scientific foundation for a hydrolysis-free, marine-derived approach to combating sun-induced skin aging, and sets the stage for bioassay-guided fractionation to pinpoint the oyster’s active principles.

Subject of Research: Pearl oyster mucus extract protects against UVA-induced skin photoaging in cells and mice

Article Title: Protective effects of an aqueous extract from Pinctada fucata martensii mucus on ultraviolet A-induced skin photoaging: in vitro and in vivo evidence

Article References: Cao, A., Wang, X., Quan, S., Qin, Y., Cai, W., & Quan, J. (2026). Protective effects of an aqueous extract from Pinctada fucata martensii mucus on ultraviolet A-induced skin photoaging: in vitro and in vivo evidence. Frontiers in Natural Products, 5, Article 1961314. https://doi.org/10.3389/fntpr.2026.1961314

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1961314

Keywords: pearl oyster, Pinctada fucata martensii, UVA, photoaging, skin aging, marine natural products, taurine, betaine, collagen, ergothioneine, senescence, NF-kappaB

Researchers Marzieh Soheili and Hamed Gilzad Kohan of Western New England University built a quantitative systems pharmacology, or QSP, model that connects three layers of biology into a single simulation: the pharmacokinetics of glucosamine absorption and delivery to synovial fluid, the turnover of glycosaminoglycans, the sponge-like matrix molecules that give cartilage its resilience, and the clinical endpoints that patients and radiologists actually measure, namely joint space width on X-rays and pain scores on the WOMAC scale. The goal was to test whether the conflicting trial results could be reconciled by differences in drug exposure at the target tissue, rather than by mysterious differences in biology.

To build the model, the team conducted a systematic review of the literature through PubMed, retrieving 177 randomized controlled trials of glucosamine in osteoarthritis. From 145 eligible studies, they selected five landmark datasets for calibration and validation: the three-year structural trials by Reginster and Pavelka, the GAIT pain trial, the Spanish GUIDE trial for independent validation, and the MOVES combination-therapy trial as an exploratory stress test. The model was implemented as a system of ordinary differential equations in MATLAB, with five free parameters estimated against eighteen aggregate observations from the published trials and all pharmacokinetic inputs fixed from literature values.

The calibration performance was strikingly good. The model reproduced the three-year joint space width treatment effect with a predicted value of 0.211 millimeters against an observed 0.240 millimeters, a 12 percent error, and it tracked the 24-week pain trajectories of both the placebo and glucosamine arms of GAIT within roughly ten percent. External validation against the GUIDE trial, which used the same crystalline glucosamine sulfate formulation and a true placebo arm, found that every observed pain score fell within the model’s 90 percent prediction intervals, with a mean absolute error of 3.8 WOMAC points. Notably, the model under-predicted the between-arm treatment difference in GUIDE, predicting 1.4 points of benefit versus the observed 5.0, which the authors attribute to their deliberate choice of a structure-dominated pain mechanism with only a minor direct analgesic component.

But the study’s most consequential finding is a cautionary one. The model could only reproduce the European structural benefit because it assumed an anti-catabolic potency anchor, an IC50 of 3.0 micrograms per milliliter, that places achievable joint concentrations on the steep part of the drug’s inhibition curve. When the team re-calibrated the model across the concentration range at which glucosamine’s anti-inflammatory effects are actually observed in laboratory studies, roughly 10 to 1,000 micrograms per milliliter, the predicted structural benefit collapsed below the minimal clinically important difference of 0.1 millimeters and the fit degraded substantially. Measured steady-state synovial concentrations after a standard 1,500 milligram dose are only about 0.78 micrograms per milliliter, one to three orders of magnitude below the levels that suppress cartilage degradation in cell experiments.

This potency mismatch offers a mechanistic explanation for the inconsistent trial record. If glucosamine’s true potency at its molecular target corresponds to the in vitro range, then even optimistic assumptions about oral absorption cannot deliver enough drug to the joint to meaningfully inhibit the IL-1beta and NF-kappaB signaling pathways that drive matrix breakdown. Under that scenario, the predicted disease-modifying effect largely disappears, and the positive European results become difficult to explain by pharmacology alone. The authors are explicit that their optimistic predictions, including a minimum effective dose of about 750 milligrams per day, an 83 percent responder rate at the standard dose, and consistent benefit across all severity stages, are all conditional on the same potency assumption and on calibration data from industry-sponsored trials that independent studies have not replicated.

The model also weighs in on a formulation debate that has shaped the glucosamine market for years. The base model assumed that crystalline glucosamine sulfate is about twice as bioavailable as the hydrochloride salt, which would partly explain why European trials using the sulfate form succeeded where GAIT, using the hydrochloride, did not. But recent pharmacokinetic work found no significant difference in systemic exposure between crystalline and regular glucosamine sulfate, and crystallographic analyses have shown that commercial glucosamine sulfate products are actually physical mixtures of glucosamine chloride and potassium or sodium salts rather than true sulfate salts. Because all of these forms dissociate in gastric fluid to release the same active glucosamine cation, the salt-form explanation for the trial discrepancy now looks shaky, and the model’s own sensitivity analysis shows that equalizing bioavailability shifts the minimum effective dose upward to 1,500 milligrams per day, precisely the dose at which independent trials have failed.

Beyond diagnosing the controversy, the framework generates forward-looking insights that illustrate why regulators are increasingly embracing model-informed drug development. Simulations predicted a near-linear relationship between oral bioavailability and treatment effect, suggesting that raising bioavailability from 22 to 40 percent could boost the structural benefit by roughly 73 percent without any dose increase. Because glucosamine is absorbed mainly through glucose transporters rather than passive diffusion, conventional permeability enhancers may not help, but preclinical strategies such as chitosan-based formulations, liposomes, and a peptide prodrug targeting the intestinal PepT1 transporter have shown promise in laboratory studies. The duration simulations also found that structural benefit continues accumulating through five years without plateau, supporting long-term treatment for patients who respond.

The work arrives at a moment when the regulatory landscape is shifting in its favor. The FDA Modernization Act 2.0, signed in December 2022, removed the blanket mandate for animal testing and explicitly authorized computational models as alternatives, and QSP submissions to the agency have grown steadily, exceeding 80 in 2023 alone. Osteoarthritis, which affects an estimated 595 million people worldwide and is projected to rise by 75 to 95 percent by 2050, still has no approved disease-modifying drug, and the authors argue that mechanistic models calibrated to human data could reduce the late-stage failures that have plagued the field. The complete MATLAB pipeline, including all calibration, bootstrap, and simulation scripts, has been released publicly on GitHub for independent replication.

Ultimately, the study’s value lies less in endorsing glucosamine than in stating precisely what would have to be true for it to work. The model shows that a disease-modifying effect requires both sufficient anti-catabolic potency and adequate joint exposure, and it demonstrates that current evidence does not establish that either condition is met at clinically achievable concentrations. For a supplement whose benefits have been argued about for a quarter century, that kind of quantitative clarity, mapping exactly where the pharmacology falls short and what a better formulation would need to achieve, may prove more useful than another round of contradictory trials. The glucosamine controversy, it turns out, may have been a pharmacokinetic question all along, and now it finally has numbers attached.

Subject of Research: A quantitative systems pharmacology model of glucosamine sulfate pharmacokinetics, cartilage matrix dynamics, and clinical outcomes in knee osteoarthritis

Article Title: A mechanistic quantitative systems pharmacology framework for glucosamine sulfate in knee osteoarthritis: linking exposure, cartilage biology, and clinical outcomes

Article References: Soheili, M., & Gilzad Kohan, H. (2026). A mechanistic quantitative systems pharmacology framework for glucosamine sulfate in knee osteoarthritis: linking exposure, cartilage biology, and clinical outcomes. Journal of Pharmacy & Pharmaceutical Sciences, 29, Article 16471. https://doi.org/10.3389/jpps.2026.16471

Image Credits: AI Generated

DOI: 10.3389/jpps.2026.16471

Keywords: glucosamine, osteoarthritis, quantitative systems pharmacology, cartilage, bioavailability, joint space width, WOMAC, disease-modifying osteoarthritis drug, model-informed drug development, pharmacokinetics, NF-kappaB, glycosaminoglycan

The new systematic review and network meta-analysis, published in Frontiers in Physiology by researchers from Capital University of Physical Education and Sports, Anhui Polytechnic University, and Changzhou University, synthesized 82 randomized controlled trials involving 6,493 adults with a mean age of 71.04 years. The team compared four structured exercise modalities: aerobic training (AT), resistance training (RT), combined aerobic-plus-resistance training (AT+RT), and multicomponent exercise (MCEx), which integrates three or more training types including balance or flexibility work. Their outcomes of interest were three core inflammatory biomarkers: interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α), the molecular fingerprints of inflammaging.

Methodologically, the study went beyond a conventional meta-analysis. The authors first ran a three-level multilevel meta-analysis to handle a problem most prior syntheses ignored: the statistical dependency created by multi-arm trials, in which one study compares several exercise groups against a shared control. Treating those correlated effect sizes as independent artificially inflates precision and biases estimates. They then performed a frequentist random-effects network meta-analysis, combining direct and indirect evidence to rank all four modalities simultaneously, using the SUCRA statistic, the surface under the cumulative ranking curve, to express each treatment’s probability of being the most effective. Finally, a double subgroup analysis stratified results by both exercise type and participants’ health status, distinguishing healthy older adults from those living with chronic diseases such as hypertension, type 2 diabetes, sarcopenia, and COPD.

The headline result is encouraging. Compared with control conditions, structured exercise significantly reduced all three biomarkers: IL-6 fell with a standardized mean difference (SMD) of -0.31, CRP fell with an SMD of -0.44, and TNF-α fell with an SMD of -0.40, all statistically significant. In plain terms, exercise training acts as a genuine, measurable anti-inflammatory intervention in people over 60, producing effects of small-to-moderate magnitude across a heterogeneous pool of trials lasting from 4 to 72 weeks, most commonly 12 weeks at three sessions per week.

The comparative rankings are where the study gets interesting. In the network meta-analysis, aerobic training ranked first for both IL-6 (SUCRA 84.6%) and TNF-α (SUCRA 97.5%, with a striking 90.6% probability of being the single best intervention). Aerobic training also produced statistically significant reductions versus control on all three markers, with the TNF-α effect (SMD = -0.97) the largest observed. Resistance training, by contrast, ranked first for CRP (SUCRA 89.1%, 65.1% probability of being best), with a significant effect versus control (SMD = -0.68), but no significant effects on IL-6 or TNF-α. Combined training and multicomponent exercise showed positive trends but did not reach statistical significance against control in the network model, and MCEx consistently sat at or near the bottom of the rankings.

The double subgroup analysis added a clinically important layer of nuance. For older adults with chronic diseases, resistance training and combined training significantly improved IL-6 (SMDs of -0.685 and -0.531, respectively) and CRP levels, suggesting that loading the muscles may be particularly valuable when an elevated inflammatory burden is already present. For healthy older adults, the opposite pattern emerged for TNF-α: aerobic training was the only modality with a statistically significant effect (SMD = -0.872), while none of the four modalities reliably lowered TNF-α in the chronic disease group. Health status, in other words, may modify which exercise stimulus delivers the strongest anti-inflammatory return, a finding no previous meta-analysis had systematically tested.

Why would different modalities target different molecules? The authors point to plausible mechanisms rather than proven pathways, since the included trials did not measure molecular signaling directly. Aerobic training is thought to dampen the nuclear factor kappa B (NF-κB) pathway, the master transcriptional switch for pro-inflammatory genes, in part by up-regulating microRNA-146a, a negative regulator that suppresses key adapter molecules in innate immune signaling. Resistance training may work through a different route: reshaping body composition, shrinking the adipose tissue depots that secrete inflammatory cytokines, and boosting anti-inflammatory cytokines such as IL-10, thereby improving the IL-10-to-TNF-α ratio. CRP, produced by the liver largely in response to IL-6, may respond especially well to interventions that alter metabolic and adiposity-related signals, which could explain resistance training’s edge on that marker.

Before anyone rewrites their exercise prescription, however, the authors are emphatic about the caveats. Under the GRADE framework, the certainty of evidence for all three outcomes was rated very low. Of the 82 trials, 53 carried an overall high risk of bias, mostly because blinding participants and trainers in exercise studies is notoriously difficult, and only 14 trials were judged low risk. Statistical heterogeneity was high across the board (I² of 82% for IL-6, 75.5% for CRP, and 88.8% for TNF-α), and funnel-plot tests suggested publication bias for IL-6 and CRP. Notably, trim-and-fill analysis imputed missing studies and produced even larger effect estimates, meaning the bias does not reverse the overall direction of the findings. But the ranking numbers deserve humility: aerobic training’s 54.7% probability of being best for IL-6 leaves roughly a 45% chance another modality is truly superior.

The study is candid about its own discrepancies too. The multilevel subgroup analysis suggested combined training was the strongest modality for IL-6, while the network meta-analysis put aerobic training on top. The authors attribute this to the different analytical frameworks: the network model exploits indirect comparison paths through shared controls and may better integrate all available information, whereas traditional subgroup analysis uses only direct comparisons. Reassuringly, formal inconsistency tests and node-splitting found no significant conflict between direct and indirect evidence, and sensitivity analyses varying the assumed within-study correlation and removing one study at a time left the conclusions essentially intact.

The bottom line is exploratory but actionable in spirit. All active exercise modalities beat no exercise at lowering inflammaging markers, which is the most robust conclusion in the dataset. The rankings hint that aerobic training is the most probable best choice for IL-6 and TNF-α, resistance training for CRP, and that older adults with chronic disease may gain the most from resistance-based or combined programs, while multicomponent exercise shows no consistent anti-inflammatory advantage despite its other well-documented benefits for balance and function. With the authors stressing that no definitive clinical recommendations can yet be made, they call for larger, rigorously blinded trials with standardized protocols, head-to-head modality comparisons, and dose-response analyses. Until then, the message to an aging population is familiar but now better quantified: keep moving, and let the biomarkers decide the details.

Subject of Research: Comparative anti-inflammatory effects of exercise training modalities on IL-6, CRP, and TNF-α in older adults

Article Title: Comparative efficacy of aerobic training, resistance training, combined training, and multicomponent exercise on interleukin-6, C-reactive protein, and tumor necrosis factor-α levels in older adults (≥60 years): a systematic review and network meta-analysis

Article References: Li, W., Chu, R., Xie, Y., Du, Y., & Ni, T. (2026). Comparative efficacy of aerobic training, resistance training, combined training, and multicomponent exercise on interleukin-6, C-reactive protein, and tumor necrosis factor-α levels in older adults (≥60 years): a systematic review and network meta-analysis. Frontiers in Physiology, 17, Article 1837579. https://doi.org/10.3389/fphys.2026.1837579

Image Credits: AI Generated

DOI: 10.3389/fphys.2026.1837579

Keywords: inflammaging, aerobic training, resistance training, network meta-analysis, interleukin-6, C-reactive protein, TNF-alpha, older adults, systematic review, exercise physiology, chronic inflammation, NF-kappaB

The new probe, named rsmiRFPnano, belongs to a family of photoreceptors called cyanobacteriochromes, or CBCRs, found in cyanobacteria. These proteins normally require only a single GAF domain to bind their light-sensing chromophore, making them far more compact than the bacteriophytochromes that previously dominated near-infrared photoacoustic imaging. Bacteriophytochrome-based probes, even in their truncated forms, exceed 55 kilodaltons and demand the full three-domain PAS-GAF-PHY assembly to bind biliverdin IXalpha, the heme-breakdown product that mammalian cells supply naturally. That bulk has constrained how these probes can be fused to other proteins or incorporated into reporters. The research team, led by Vladislav Verkhusha of the University of Helsinki and Albert Einstein College of Medicine together with Junjie Yao of Duke University, reasoned that a verdin-specific CBCR lineage, whose members naturally accept biliverdin-like chromophores and absorb at red-shifted wavelengths, could be coaxed into a mammalian-compatible photoswitch a third of the size.

The starting material was the third GAF domain of a CBCR called JSC1_58120 from the cyanobacterium Leptolyngbya sp. JSC1. In its native form, the domain showed promising photochemistry in bacteria, flipping reversibly between a near-infrared-absorbing ground state with an absorbance peak at 715 nanometers and a far-red-absoring photoproduct peaking at 650 nanometers. But in mammalian cells it performed poorly, a fatal flaw for any genetically encoded in vivo probe. Mutations in the biliverdin-binding pocket tend to disrupt the delicate photocycle, so the team took a different tack: iterative saturation mutagenesis aimed at structural regions outside the pocket, targeting paired residues in the N- and C-terminal helices that face each other in the folded structure. Four sequential rounds of evolution, screened first in bacteria and then validated in transfected mammalian cells, yielded rsmiRFPnano, a 163-residue protein carrying seven substitutions that collectively tripled mammalian-cell fluorescence relative to the parent while preserving, and even slightly enhancing, the light-absorption machinery.

The numbers behind the engineered protein are striking. rsmiRFPnano exhibits molar extinction coefficients of 85,000 and 88,000 per molar per centimeter in its two photoswitchable states, among the highest values reported for genetically encoded near-infrared probes. Its pKa values of roughly 4.2 in both states mean spectral properties remain stable across the physiological pH range, and native gel electrophoresis confirmed it behaves as a monomer with no detectable aggregation. In HEK293T cells, flow cytometry showed a 3.5-fold fluorescence increase over the parental protein, and the probe accumulated with kinetics comparable to enhanced green fluorescent protein, reaching half-maximal signal in about 27 hours with an intracellular half-life of roughly 18 hours. These are the characteristics of a probe built to survive and function inside living cells, not just in a cuvette.

The real magic, however, lies in how the probe exploits its photoswitching. Under alternating illumination with 635 and 725 nanometer light, rsmiRFPnano cycles between an ON state that absorbs strongly in the near-infrared and an OFF state that absorbs in the far-red. By acquiring photoacoustic images in both states and subtracting the OFF image from the ON image, the technique known as differential photoacoustic tomography isolates only the signals that actually switch, suppressing the static background from hemoglobin and water. In phantom experiments, purified rsmiRFPnano at 17 micromolar concentration embedded in whole blood produced contrast-to-noise ratios essentially identical to those measured in buffer, demonstrating that the differential contrast is virtually independent of the surrounding optical environment. The team estimated a noise-equivalent detection sensitivity of about 0.33 micromolar against a whole-blood background, a level of performance that transforms what is detectable inside a living animal.

To prove the probe could report on biology rather than just its own presence, the researchers built transcriptional reporters for two master regulators of inflammation, NF-kappaB and AP-1. Each construct placed tandem response elements upstream of a minimal promoter driving rsmiRFPnano expression, so that pathway activation directly translated into probe production. In cultured cells, the reporters showed minimal basal leakiness and strong, dose-dependent induction upon stimulation with tumor necrosis factor or phorbol ester. The team then delivered the reporters to mouse livers via hydrodynamic transfection and induced systemic acute inflammation with lipopolysaccharide. Differential photoacoustic imaging tracked the molecular response longitudinally over five days, revealing that the NF-kappaB reporter peaked rapidly at 12 hours post-treatment while the AP-1 reporter rose more gradually to a maximum at 48 hours, a temporal distinction consistent with known signaling dynamics in liver injury. Control animals receiving saline instead of the inflammatory stimulus showed peak signals fivefold to sevenfold weaker, confirming that the readouts reflected genuine inflammation rather than transfection stress.

The imaging platform went further by integrating super-resolution ultrasound localization microscopy on the same system. Microbubble tracking resolved the hepatic microvasculature in three dimensions and co-registered it with the molecular photoacoustic maps, revealing significant decreases in liver blood-flow speed and blood volume at 48 hours after lipopolysaccharide treatment. An integrated inflammation index, combining the spatial extent and intensity of reporter activation, rose in parallel with the hemodynamic decline. To validate the in vivo findings independently, the collaborators performed multiplexed spatial proteomics using CODEX imaging with a 50-antibody panel on liver sections collected at baseline and at 24 and 72 hours. Single-cell segmentation and clustering showed immune cell infiltration peaking at 24 hours, with macrophages and CD45-positive cells surging early, while inflamed hepatocytes expressing the MHC class I molecule H-2Db dominated by 72 hours. The cellular choreography mapped ex vivo matched the temporal patterns the living-imaging approach had captured noninvasively.

Perhaps the most forward-looking application came from fusing rsmiRFPnano into nanobody scaffolds. Nanobodies, the 15-kilodalton single-domain antibody fragments derived from camelid heavy chains, bind intracellular antigens with high specificity, but unbound nanobodies accumulate and generate background that obscures the signal of interest. The team’s solution, called rsNIR-Fbs, inserts rsmiRFPnano into a loop in the nanobody’s third framework region, distal from the antigen-binding surface. The design makes the fusion protein unstable unless it binds its target: unbound probes are rapidly degraded by the proteasome, while antigen-bound probes are stabilized and generate photoacoustic signal. AlphaFold3 modeling confirmed the insertion preserves the canonical VHH beta-sandwich fold and the antigen-binding loops. The researchers built rsNIR-Fbs against enhanced green fluorescent protein, HIV-1 gp41, and the SARS-CoV-2 spike receptor-binding domain, and in each case fluorescence appeared only when the cognate antigen was coexpressed.

In vivo proof of concept followed in mice whose livers expressed green fluorescent protein via hydrodynamic transfection while the anti-GFP rsNIR-Fb was delivered systemically through an adeno-associated virus. Differential photoacoustic imaging combined with ultrasound localization microscopy revealed strong, spatially confined signals in the liver, co-registered with the microvasculature, and nothing in control organs. When the antigen plasmid was omitted, virtually no differential signal appeared, demonstrating that the photoacoustic output was governed by antigen presence rather than probe delivery or nonspecific accumulation. The result establishes a new class of conditional probes in which the imaging signal itself is gated by molecular recognition inside cells, within organs whose dense blood supply would ordinarily defeat molecular specificity.

The implications extend well beyond inflammation models. Because rsmiRFPnano is threefold smaller than the most compact bacteriophytochrome-derived photoacoustic probes, it offers a flexible scaffold for reporters of virtually any transcriptional pathway, from oncogenic signaling to neuronal plasticity, and the rsNIR-Fb strategy opens photoacoustic immuno-imaging to endogenous intracellular targets including signaling intermediates, viral antigens, and cancer-associated proteins. The authors note that further improvements in biliverdin binding and switching contrast should push detection limits lower still. What the study ultimately delivers is a convergence of protein engineering, acoustic detection, and spatial omics validation: a genetically encodable molecular flashlight, small enough to fit inside a nanobody, bright enough to be heard through centimeters of blood-filled tissue, and switchable enough to be distinguished from everything the body does on its own. For a field that has long struggled to make molecular signals audible above the noise of biology, that is a genuinely resonant advance.

Subject of Research: Engineering of a compact cyanobacteriochrome-derived photoswitchable protein for photoacoustic molecular imaging of inflammation and intracellular antigens

Article Title: Near-infrared photochromic miniprotein enables photoacoustic molecular imaging of acute inflammation and intracellular antigens

Article References: Oliinyk, O. S., Xu, Y., Luo, J., Tokarchuk, K. O., Manoilov, K. Y., van de Klashorst, J., Eyring, M. P., Wang, M.-E., Chen, M., Song, P., Hickey, J. W., Yao, J., & Verkhusha, V. V. (2026). Near-infrared photochromic miniprotein enables photoacoustic molecular imaging of acute inflammation and intracellular antigens. Nature Methods. https://doi.org/10.1038/s41592-026-03255-y

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03255-y

Keywords: photoacoustic tomography, rsmiRFPnano, cyanobacteriochrome, near-infrared imaging, NF-kappaB, AP-1, inflammation, nanobody, biliverdin, molecular imaging, protein engineering, spatial omics

The research, led by Thinh Thi Kim Truong, Shinsuke Fujii and Tamotsu Kiyoshima of Kyushu University in Japan, together with collaborators in Finland, Germany and Japan, focused on ARL4C, or ADP-ribosylation factor-like 4C, a small GTP-binding protein that has emerged as a key player in oral cancer biology. The team’s central question was deceptively simple: how does a gene operating inside cancer cells manage to reprogram healthy stromal cells at a distance so that they begin producing a potent bone-destroying signal? The answer they uncovered involves a relay of inflammatory messages, culminating in the activation of the transcription factor RelA, the major subunit of the NF-kappaB family, inside the fibroblasts themselves.

To dissect the mechanism, the researchers took a systematic approach. They cultured stromal cells in the presence of conditioned medium harvested from oral squamous cell carcinoma cells, effectively exposing the stromal cells to the full cocktail of soluble factors that tumors release into their surroundings. They then performed comprehensive RNA sequencing on the exposed stromal cells and ran pathway enrichment analyses to identify which signaling programs had been switched on. Two pathways stood out with striking clarity: NF-kappaB and Stat3. Both are classic inflammatory and survival pathways, and their coordinated activation suggested that the tumor-conditioned medium was driving the stromal cells into a pro-inflammatory state rather than merely nudging them toward RANKL production through a single linear signal.

The team then moved from observation to causation. Using small interfering RNA to knock down specific gene products, along with pharmacological inhibitors targeting candidate pathways, they tested which of the activated programs was actually required for RANKL induction. The result was unambiguous: blocking RelA, the principal DNA-binding subunit of NF-kappaB, significantly reduced the tumor-induced expression of RANKL in the stromal cells. In other words, without RelA, the fibroblasts exposed to tumor secretions no longer became efficient producers of the osteoclast-activating ligand. This positioned RelA not as a passive correlate but as the critical molecular gatekeeper through which the tumor’s influence on stromal RANKL flows.

With the stromal side of the axis mapped, the investigators turned to the tumor side, and this is where ARL4C entered the story. When the researchers manipulated ARL4C expression in the oral cancer cells, they found that the oncogene promoted the secretion of proinflammatory cytokines from the tumor cells. These cytokines, in turn, established a sustained, RelA-mediated inflammatory response in the stromal fibroblasts. The picture that emerges is a two-step relay: ARL4C inside the cancer cell drives the release of inflammatory messengers, and those messengers travel across the tumor-stroma boundary to lock the fibroblasts into an NF-kappaB-dependent program that includes robust RANKL production. The fibroblasts, in this scheme, are not innocent bystanders but active participants, converted into what the authors describe as a critical, non-canonical source of RANKL driving jawbone destruction.

Crucially, the team did not rely on cell culture alone. They examined human clinical specimens of oral squamous cell carcinoma using immunohistochemistry, the technique that allows specific proteins to be visualized in their tissue context. The staining revealed that phosphorylated RelA, the activated form of the transcription factor, and RANKL were co-expressed in stromal fibroblasts marked by alpha-smooth muscle actin, or alpha-SMA, a signature of activated cancer-associated fibroblasts. These double-positive cells clustered at the bone-invasive front of the tumor, the very frontier where cancer meets bone and where resorption is most aggressive. Perhaps most strikingly, the signal was detected even in areas distant from the tumor nests, indicating that the inflammatory instruction to produce RANKL can propagate through the stroma beyond the immediate vicinity of the cancer cells, potentially explaining why bone destruction in these tumors can be so extensive.

The identification of alpha-SMA-positive fibroblasts as the RANKL-producing population carries significant implications for how scientists think about cancer-induced bone disease. Much of the classical work on RANKL in bone metastasis has focused on osteoblasts, the bone-forming cells that normally express RANKL as part of the bone remodeling cycle, or on immune cells such as activated T lymphocytes. The new findings add stromal fibroblasts to that roster and suggest that in oral cancer, the tumor does not simply co-opt the normal remodeling machinery; it actively manufactures a new population of RANKL-secreting cells from the connective tissue it invades. This non-canonical route may help explain the particularly aggressive and locally destructive behavior of oral squamous cell carcinoma compared with tumors that metastasize to bone through the bloodstream.

From a therapeutic standpoint, the study points to the ARL4C-RelA axis as a potential target. If ARL4C in cancer cells is the upstream driver of cytokine secretion, and RelA in fibroblasts is the downstream executor of RANKL expression, then interrupting either node of the relay could, in principle, dampen the production of the osteoclast-activating ligand and slow or prevent jawbone destruction. The authors suggest that targeting this axis might represent a promising strategy for suppressing stromal RANKL expression and improving quality of life for patients with oral squamous cell carcinoma. Such an approach would complement existing antiresorptive treatments, which act on osteoclasts directly but do nothing to stop the tumor-driven signals that keep recruiting new bone-destroying cells. It is worth emphasizing, however, that the therapeutic implication remains a hypothesis grounded in preclinical experiments and human tissue correlation; clinical testing would be needed before any such strategy reaches patients.

The methodological rigor of the work deserves note as well. By combining unbiased transcriptomics with targeted perturbation, the researchers avoided the trap of assuming in advance which pathway mattered; the RNA sequencing pointed them toward NF-kappaB and Stat3, and only the inhibition experiments established that RelA was the indispensable component for RANKL induction. The pharmacological validation strengthens the case that the effect is druggable in principle, and the immunohistochemistry on patient specimens anchors the entire mechanistic story in human disease. The study was conducted in compliance with the Declaration of Helsinki, with ethical approval from the Kyushu University Research Ethics Committee, and the work received support from JSPS KAKENHI grants along with several Japanese and Finnish research foundations.

For the growing number of patients diagnosed with oral squamous cell carcinoma each year, jawbone invasion is one of the most feared consequences of the disease, driving extensive surgical resections and long-term functional impairment. By revealing that a single oncogene in the cancer cells can conscript neighboring fibroblasts into a bone-destroying role through a defined inflammatory pathway, this study transforms a poorly understood clinical phenomenon into a molecular circuit with named components and identifiable points of intervention. The next steps, the findings suggest, lie in exploring whether blocking ARL4C-driven cytokine release or RelA activation in the stroma can preserve bone in experimental models, and ultimately in determining whether patients whose tumors harbor high ARL4C expression might benefit from therapies aimed not at the cancer cells themselves but at the corrupted dialogue they conduct with the tissue around them.

Subject of Research: ARL4C-driven tumor-stroma inflammatory signaling and RANKL-mediated bone destruction in oral squamous cell carcinoma

Article Title: ARL4C in oral cancer cells promotes stromal RANKL expression via a RelA-dependent inflammatory axis in stromal fibroblasts

Article References: Truong, T. T. K., Fujii, S., Hasegawa, K., Matsumoto, S., Kurppa, K. J., Heikinheimo, K., Petersen, J., Li, A., Elenius, K., Jimi, E., & Kiyoshima, T. (2026). ARL4C in oral cancer cells promotes stromal RANKL expression via a RelA-dependent inflammatory axis in stromal fibroblasts. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06620-8

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06620-8

Keywords: oral squamous cell carcinoma, ARL4C, RANKL, RelA, NF-kappaB, stromal fibroblasts, osteoclastogenesis, jawbone destruction, tumor microenvironment, inflammatory cytokines, cancer-associated fibroblasts, bone invasion

The starting point of the review is the pathogenesis of atherosclerosis itself. The disease begins when the endothelium, the single layer of cells lining the arterial wall, becomes dysfunctional under the combined assault of high blood pressure, disturbed blood flow, smoking, diabetes and oxidized lipids. Damaged endothelial cells express adhesion molecules such as ICAM-1 and VCAM-1, which allow circulating monocytes to stick to the vessel wall and squeeze between them into the intima. There, the monocytes mature into macrophages that engulf modified low-density lipoprotein particles, swell into foam cells and release a cocktail of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. Vascular smooth muscle cells migrate and proliferate, stabilizing or destabilizing the growing plaque, and the resulting lesions can rupture catastrophically, triggering the clots that cause myocardial infarction and stroke. Every one of these steps, the authors emphasize, is a potential point of pharmacological or nutritional intervention.

Oxidative stress sits at the center of this cascade. Reactive oxygen species generated by dysfunctional endothelial cells, mitochondria and inflammatory enzymes promote the oxidation of LDL cholesterol, converting it into the oxidized LDL that macrophages find irresistible. Oxidative stress also inactivates nitric oxide, the endothelial gas molecule that keeps vessels dilated and inflammation suppressed. The body’s first-line antioxidant defenses, superoxide dismutase, catalase and glutathione peroxidase, normally hold these reactive species in check, and experimental work cited in the review shows that boosting these enzymes in mice inhibits smooth muscle proliferation and offsets pro-atherogenic gene expression in human endothelial cells. Yet the history of antioxidant therapy in cardiology is humbling: large randomized trials of vitamin E and C supplementation, including the ASAP study, the HOPE trial and the GISSI-Prevenzione trial, largely failed to reduce cardiovascular events. That failure is precisely why the field has shifted its attention to polyphenols, which act less like blunt radical scavengers and more like modulators of cellular signaling networks.

The review’s mechanistic core describes how specific polyphenols engage the master switches of vascular inflammation. Nuclear factor-kappa B, or NF-κB, is the transcription factor that switches on the genes for adhesion molecules and cytokines in endothelial cells and macrophages; the mitogen-activated protein kinase pathways feed into the same inflammatory program. Quercetin, for example, has been shown in macrophage models to disrupt the association between phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88, thereby dampening both MAPK/AP-1 and IKK/NF-κB-driven production of inflammatory mediators. On the protective side of the redox balance, polyphenols activate the Keap1-Nrf2 pathway, which induces the expression of endogenous antioxidant enzymes through the antioxidant response element. Anthocyanins, the pigments in berries, have been reported to activate Nrf2-ARE signaling as a modulator of redox homeostasis, while natural products broadly are increasingly recognized as activators of Nrf2 signaling with cardiovascular protective potential.

Resveratrol, the stilbene famous from red grapes, illustrates how deeply these compounds can reach into cellular metabolism. Structural studies reviewed by the authors show that resveratrol allosterically stimulates SIRT1, the NAD-dependent deacetylase linked to cellular stress resistance and longevity, and downstream effects extend to AMP-activated protein kinase, a central regulator of energy metabolism. In the context of cholesterol handling, resveratrol has been associated with improved cholesterol metabolism and with enhanced expression of the transporters ABCA1 and ABCG1, which export cholesterol from macrophage foam cells in the first step of reverse cholesterol transport. Catechins from green tea, particularly epigallocatechin gallate, and curcumin from turmeric each carry their own portfolio of anti-inflammatory, antioxidant and lipid-modulating actions documented across in vitro and animal studies. The picture that emerges is not one molecule, one target, but a network pharmacology in which dietary compounds nudge several atherogenic processes simultaneously.

What does the human evidence show? Clinical studies and meta-analyses reviewed by the authors suggest potential improvements in endothelial function, lipid profiles, blood pressure and inflammatory biomarkers after polyphenol-rich dietary interventions. Cocoa flavanols have produced some of the most consistent results: randomized trials, including the Flaviola Health Study, found that flavanol intake improved endothelial function and Framingham Risk Score in healthy adults, and a dose-response meta-analysis of randomized trials confirmed a relationship between cocoa flavanol intake and endothelial function. Olive oil polyphenols have their own track record: a randomized trial published in Annals of Internal Medicine showed that polyphenol-rich olive oil favorably modified heart disease risk factors, and later work found improvements in lipoprotein particle atherogenic ratios. In the PREDIMED trial substudy, higher polyphenol intake from a Mediterranean diet was associated with decreased inflammatory biomarkers related to atherosclerosis, and a crossover trial of hydroxytyrosol and punicalagin supplementation improved early markers of asymptomatic atherosclerosis in adults.

Yet the review is careful to flag the caveats, and they are substantial. Findings across clinical studies remain heterogeneous, and most of the supportive evidence rests on surrogate outcomes, such as flow-mediated dilation, oxidized LDL levels or C-reactive protein, rather than hard endpoints like myocardial infarction or cardiovascular death. Some trials are strikingly negative: a randomized placebo-controlled crossover trial found that resveratrol did not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects, even as a separate triple-blind trial reported that a grape extract containing resveratrol decreased oxidized LDL and apolipoprotein B in patients on primary prevention. Inter-individual variability looms large, since human studies show wide differences in how people metabolize and absorb polyphenolic compounds, driven by genetics, gut microbiota composition and dietary context. The authors conclude that clinical efficacy in atherosclerosis management remains uncertain and call for well-designed, long-term studies to clarify therapeutic relevance, optimal dosing and safety.

Two emerging strategies may help close the gap between promising mechanisms and clinical reality. The first is bioavailability engineering. Polyphenols are notoriously poorly absorbed, extensively metabolized and rapidly cleared, which limits the concentrations reaching arterial tissue. Nano-delivery systems, including liposomal and polymeric nanoparticle formulations, are being developed to protect these compounds through digestion and enhance their uptake; a recent randomized double-blind trial of a double-layered nano-liposomal curcumin formulation demonstrated enhanced bioavailability in humans, and pharmacokinetic studies of novel resveratrol formulations are following a similar path. The second strategy targets the gut microbiota, which transforms many parent polyphenols into metabolites that may actually be the biologically active species. Reviews of probiotic and phenolic approaches to atherosclerosis suggest that microbiota-targeted interventions could amplify cardioprotective effects, although the authors note that clinical efficacy for both nano-formulations and microbiota-directed approaches remains to be established.

Safety, too, deserves attention. Polyphenols are not automatically benign at high doses: they can interact with medicines, and reviews have catalogued possible side effects and drug interactions, while meta-analyses of curcumin and turmeric supplementation have examined effects on liver function with mixed findings. The review’s overall verdict is measured but constructive: antioxidants and dietary polyphenols may provide complementary approaches for cardiovascular risk reduction, best delivered through polyphenol-rich dietary patterns such as the Mediterranean diet rather than high-dose isolated supplements, and always alongside, not instead of, established therapies like statins and blood pressure control. For a disease that remains the leading cause of death worldwide, the message is that the chemistry of everyday plant foods is genuinely interesting at the molecular level, and that the next decade of long-term clinical trials will determine whether that molecular interest can be translated into fewer heart attacks and strokes.

Subject of Research: Molecular mechanisms by which dietary polyphenols influence atherosclerosis, endothelial dysfunction, oxidative stress and vascular inflammation

Article Title: Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation

Article References: Dey, A., Gautam, M. K., Modak, K., Dutta, P. P., & Mahajon, B. (2026). Dietary polyphenols in atherosclerosis: a review of molecular mechanisms, endothelial dysfunction, oxidative stress, and vascular inflammation. Molecular Biology Reports, 53(1), Article 1712. https://doi.org/10.1007/s11033-026-12914-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12914-4

Keywords: atherosclerosis, dietary polyphenols, endothelial dysfunction, oxidative stress, vascular inflammation, NF-kappaB, Nrf2, resveratrol, quercetin, curcumin, gut microbiota, cardiovascular disease

Current treatment for the ocular disease relies heavily on corticosteroids, delivered as topical drops, injections into the eye, or oral prednisone. This approach has serious shortcomings. Studies indicate that 30 to 60 percent of patients with HTLV-1-associated uveitis experience recurrent episodes, and long-term steroid exposure can trigger cataracts, glaucoma, macular edema, epiretinal membranes, retinal degeneration, optic nerve atrophy, and bullous keratopathy. Most importantly, corticosteroids suppress inflammation without reducing the number of virus-infected cells or halting disease progression. Newer molecular targeted agents, including the anti-CCR4 antibody mogamulizumab and the immunomodulatory drug lenalidomide, have been explored, but treatment-related inflammation and adverse effects remain significant obstacles. This therapeutic gap motivated a team led by Yaru Zou and Koju Kamoi of Tokyo Medical and Dental University to investigate whether an epigenetic drug already approved for blood cancer could address the root of the ocular inflammation.

The drug in question is valemetostat, marketed as EZHARMIA, a dual inhibitor of the enzymes EZH1 and EZH2 that was approved in 2022 for adult T cell leukemia/lymphoma. Both enzymes are the catalytic components of polycomb repressive complex 2, a molecular machine that silences genes by adding three methyl groups to lysine 27 on histone H3, producing the repressive chromatin mark known as H3K27me3. Previous work had shown that EZH1 and EZH2 are overexpressed, and H3K27me3 deposition increased, in ATL cells and in cells expressing the viral oncoprotein Tax. Dual EZH1/2 inhibitors have also been reported to curb the spontaneous proliferation and exaggerated immune responses of HTLV-1-infected cells in patients with HTLV-1-associated myelopathy. What remained unknown was whether such inhibition could benefit the inflamed eye.

To find out, the researchers built a series of laboratory models centered on ARPE-19 cells, a human retinal pigment epithelial cell line chosen because the retinal pigment epithelium forms the outer blood-retinal barrier and governs retinal immune homeostasis. They exposed these ocular cells to three kinds of T cells: MT-2 cells, which carry transcriptionally active HTLV-1 and express the viral protein Tax; TL-Om1 cells, an ATL-derived line in which the virus is largely silent and Tax is low or absent; and Jurkat cells, which are uninfected and served as controls. In parallel, they treated the T cell lines themselves. Western blotting and quantitative PCR revealed that HTLV-1 infection drove significant upregulation of both EZH1 and EZH2, along with elevated H3K27me3, in infected retinal pigment epithelial cells and in MT-2 cells, with EZH1 protein rising roughly 2.5-fold in infected ocular cells and six-fold in MT-2 cells. This was the first demonstration that HTLV-1 infection induces polycomb-mediated epigenetic changes in retinal cells.

The team then treated the models with valemetostat at 0.01, 0.1, and 1 micromolar for 96 hours, concentrations selected in preliminary experiments because they harmed infected T cells while leaving normal ocular cells, including primary human trabecular meshwork cells, unaffected below 10 micromolar. The results were strikingly dependent on the model. In co-cultures of retinal cells with Tax-positive MT-2 cells, and in retinal cells directly infected with HTLV-1, the drug produced modest but statistically significant reductions in cell viability at the highest dose, accompanied by small increases in late-stage apoptosis. No such effects appeared in co-cultures with TL-Om1 or Jurkat cells. Crucially, the absolute magnitude of apoptosis remained limited, typically only 1 to 3 percent above baseline, indicating that valemetostat is not broadly toxic to retinal cells, an important safety consideration given their role in maintaining vision.

The virological findings were equally nuanced. Valemetostat did not significantly reduce the HTLV-1 proviral load in co-culture systems or in directly infected retinal pigment epithelial cells. However, in MT-2 cells themselves, 1 micromolar valemetostat significantly lowered proviral load and suppressed the messenger RNA levels of both Tax and HBZ, the two hallmark transcripts of the virus. Because MT-2 cells represent the transcriptionally active, highly infectious state of HTLV-1, while TL-Om1 represents latency, the results suggest that the drug’s antiviral effect is gated by the transcriptional status of the infected cell. Within the four-day treatment window, the authors conclude, valemetostat’s benefit to the ocular environment is likely indirect, acting primarily by quieting the most virally active cells rather than by eradicating provirus everywhere.

The most clinically relevant effects emerged in the inflammatory readouts. HTLV-1-infected T cells recovered from the eyes of patients with uveitis are known to secrete copious interleukin-6, interleukin-8, and interleukin-10, all implicated in disease. In the new study, valemetostat produced a dose-dependent increase in the anti-inflammatory cytokine IL-10 in MT-2-containing conditions, significant at 1 micromolar in the co-culture system and across all doses in MT-2 cells. This fits a mechanistic expectation: blocking EZH1/2 removes H3K27me3 marks that repress the IL-10 gene, and prior genetic studies showed that loss of EZH2 directly activates IL-10 transcription in several CD4-positive T cell subsets. Meanwhile, pro-inflammatory signals fell in a context-dependent pattern. IL-12p70 and the chemokine CXCL-10 dropped in co-cultures, IL-6 and IL-8 declined mainly in MT-2 cells, and CCL-2 fell at low doses in the MT-2 co-culture, whereas the chemokine CCL-5 was unchanged in every model.

The drug’s influence on NF-kappaB, the central inflammatory pathway that Tax hijacks to drive both viral replication and cytokine production, was more subdued. Valemetostat modestly reduced NF-kappaB p65 phosphorylation in the MT-2 co-culture at the lowest dose and slightly decreased the nuclear-to-cytoplasmic ratio of p65 in retinal cells stimulated with TNF-alpha, but it did not abolish nuclear translocation. The authors attribute this to the overwhelming strength of Tax-driven NF-kappaB activation, which a 96-hour course of EZH1/2 inhibition may be insufficient to counteract, and to the fact that NF-kappaB and cytokine networks are regulated by many factors beyond polycomb complexes. Immunofluorescence confirmed that valemetostat significantly lowered H3K27me3 in retinal cells exposed to MT-2 cells or directly infected, but not in cells co-cultured with TL-Om1 or Jurkat cells, again underscoring the model dependence of the epigenetic response.

The study also carries a cautionary note about IL-10. Although the cytokine is anti-inflammatory, it can promote the survival of HTLV-1-infected T cells and facilitate immune evasion by impairing dendritic cell antigen presentation and downregulating MHC class I molecules, and patients with aggressive ATL often show abnormally elevated IL-10. The authors therefore suggest that combining EZH1/2 inhibition with IL-10 pathway blockade could prove more effective, noting evidence that IL-10 neutralization sensitizes ATL cells to standard therapies. In the TL-Om1 model of ATL-related ocular infiltration, valemetostat failed to reduce H3K27me3, proviral load, or NF-kappaB activation within the malignant cells, yet it suppressed TL-Om1-induced CXCL10 secretion and induced dose-dependent apoptosis, pointing to a benefit mediated through the inflammatory microenvironment rather than direct tumor killing.

The authors are candid about the limitations. The work relied entirely on in vitro co-cultures and established cell lines, which cannot reproduce the blood-retinal barrier, retinal architecture, or local immune regulation of a living eye, and the intraocular pharmacokinetics of valemetostat after systemic administration remain undefined. Sex as a biological variable could not be assessed because donor-defined primary cells were not used. Even so, the findings establish a proof of concept that an approved epigenetic therapy can counteract HTLV-1-induced chromatin changes in retinal cells, dampen viral transcription in the most active infected cells, and reshape the cytokine milieu that sustains uveitis. Longer treatment studies, in vivo models, and patient-derived systems will be needed to determine whether these modest, context-dependent effects can be translated into a genuine steroid-sparing therapy for one of the most burdensome manifestations of a virus that medicine has long neglected.

Subject of Research: EZH1/2-targeted epigenetic therapy with valemetostat for HTLV-1-associated uveitis

Article Title: Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms

Article References: Zou, Y., Kamoi, K., Yang, M., Zong, Y., Zhang, J., & Ohno-Matsui, K. (2026). Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms. iScience, 29(11), Article 117775. https://doi.org/10.1016/j.isci.2026.117775

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117775

Keywords: HTLV-1, valemetostat, EZH1, EZH2, H3K27me3, uveitis, epigenetics, PRC2, Tax, IL-10, NF-kappaB, retinal pigment epithelium

The condition the researchers targeted is one of medicine’s quiet epidemics. Metabolic dysfunction-associated steatotic liver disease, or MASLD, affects the majority of people living with diabetes, and its incidence exceeds that of diabetic kidney disease. Because early-stage disease is usually symptom-free, it is frequently missed until fat overload, inflammation, and eventually fibrosis have taken hold. Left unchecked, it can progress to steatohepatitis and cirrhosis, sharply raising the risk of liver cancer, and it independently correlates with cardiovascular events and mortality. For a sugar that delivers roughly 70 percent of the sweetness of sucrose with minimal caloric contribution, the possibility of also easing this liver burden is a striking proposition.

To test the idea, a team at Jiangsu University worked with male C57BL/6J mice, feeding them a high-fat diet for four weeks and then injecting low doses of streptozotocin, a chemical that damages the insulin-producing beta cells of the pancreas. This combination reliably produces animals with high blood glucose, abnormal blood lipids, oxidative stress, and fat-laden livers, reproducing selected features of type 2 diabetes. One week after the final injection, mice with fasting blood glucose above 11.1 millimoles per liter were considered diabetic. The diabetic animals were then split into three groups of six: one left untreated, one given D-psicose at 2.5 percent of drinking water, and one given 5.0 percent. Treatment continued for twelve weeks alongside the high-fat diet.

The results were visible before any instrument was switched on. Livers from untreated diabetic mice were enlarged and pale, the classic gross appearance of severe lipid retention, while livers from the high-dose treatment group looked reddish and smooth, closely resembling those of healthy controls. Under the microscope the differences sharpened. Hematoxylin and eosin staining revealed that diabetic livers had lost their orderly cellular architecture, with hepatocytes ballooning and filling with vacuoles. Oil Red O staining, which highlights neutral triglycerides in bright red, confirmed massive fat deposits. D-psicose reversed these defects in a dose-dependent manner, preserving hepatic structure and clearing lipid droplets most effectively at the higher dose. Body weight, which had been falling steadily as the disease progressed, also stabilized in the treated animals.

Blood chemistry told the same story from a different angle. Untreated diabetic mice carried elevated total cholesterol, triglycerides, and LDL cholesterol, along with depressed HDL, the protective fraction. They also showed raised alanine and aspartate aminotransferases, the enzymes that leak into the bloodstream when liver cells are injured, and heightened circulating levels of the inflammatory cytokines TNF-alpha, IL-6, and IL-1beta. Twelve weeks of D-psicose shifted all of these indices back toward the healthy profile, with the high-dose regimen again producing the larger effect. The pattern suggests the sugar was not merely masking symptoms but correcting an underlying imbalance in how the diabetic liver handles fat and inflammation.

The molecular explanation begins with lipid metabolism genes. In diabetic livers, the transcription factors and enzymes that drive de novo fat synthesis, SREBP-1c and FASN, were significantly upregulated, while PPAR-alpha, the master regulator of fatty acid beta-oxidation, was suppressed. D-psicose flipped this program: SREBP-1c and FASN fell in a dose-dependent fashion and PPAR-alpha recovered toward normal levels. The authors describe this as a dual mechanism of increasing expenditure and reducing intake, simultaneously blocking new fat production and burning existing fat. The treatment also restored the transcription of antioxidant enzymes SOD1 and GPX1, which diabetes had suppressed, and pushed down Col1a1 and TGF-beta1, two markers of the pro-fibrotic signaling that threatens to scar the liver permanently.

The most novel part of the study concerns the gut-liver axis. Sequencing the V3-V4 region of the bacterial 16S rRNA gene from colonic contents showed that diabetes had skewed the microbial community, inflating the Firmicutes-to-Bacteroidota ratio and expanding Proteobacteria, a phylum often associated with inflammation. At the genus level, diabetic mice had depleted Akkermansia, Lactobacillus, and several other taxa, while Alistipes, Parabacteroides, and Anaerotruncus expanded. D-psicose treatment recalibrated these imbalances, pulling the community profile back toward that of healthy controls. In parallel, the sugar repaired the intestinal wall itself: villi that had become stunted and disorganized regained their height, the tight-junction proteins ZO-1 and Occludin, which seal the gaps between epithelial cells, recovered their continuous staining pattern, and serum lipopolysaccharide, a marker of bacterial endotoxin leaking through a leaky gut, dropped significantly.

Those microbial and barrier changes coincided with a measurable shift in tryptophan chemistry. Using targeted UPLC-MS/MS, the researchers found that diabetic mice had depleted serum tryptophan, elevated kynurenine, and a raised kynurenine-to-tryptophan ratio, a signature of overactive IDO/TDO catabolism, together with reduced levels of indole-3-propionic acid, a microbially derived metabolite with known anti-inflammatory properties. D-psicose reversed every one of these abnormalities. In the liver, the enzyme TDO2, the rate-limiting step of the tryptophan-kynurenine pathway, had been overexpressed in diabetes while the aryl hydrocarbon receptor, or AhR, a nuclear sensor for microbial indole metabolites, had been suppressed. Treatment lowered TDO2 and restored AhR at both the mRNA and protein levels. At the same time, the phosphorylation ratio of NF-kappaB p65, the activated form of the central inflammatory transcription factor, fell from its diabetic high back toward normal.

Untargeted serum metabolomics reinforced the picture. Principal component analysis separated the three groups in both ionization modes, and internally validated OPLS-DA models, checked with seven-fold cross-validation and 200-permutation testing, confirmed that D-psicose shifted the metabolic profile toward that of healthy animals. KEGG enrichment pointed to pathways including tryptophan metabolism, arachidonic acid metabolism, biotin metabolism, and steroid hormone biosynthesis as candidate biological contexts for the changes. The authors are careful, however, about what these data can and cannot prove. Because 16S sequencing is taxonomic rather than functional, the study cannot show that Akkermansia or Lactobacillus actually produced the altered metabolites, and because AhR activity was never directly perturbed, the gut microbiota-tryptophan-AhR chain remains a coherent hypothesis rather than a demonstrated causal mechanism.

The limitations are acknowledged candidly. The HFD/STZ model does not capture the full heterogeneity or natural history of human diabetic liver disease, the sample size was modest at six animals per group, and fasting glucose was used only to confirm diabetes induction, with no assessment of glucose tolerance, insulin sensitivity, or glycated hemoglobin. No fecal microbiota transplantation, germ-free experiments, or pharmacological AhR ligands were deployed to test causality. Still, the convergence of evidence is notable: a widely available rare sugar improved liver histology, blood lipids, inflammatory cytokines, antioxidant defenses, and fibrosis markers in diabetic mice, all while reshaping the gut ecosystem, restoring barrier integrity, and rebalancing a microbial-metabolic signaling axis increasingly implicated in metabolic disease. If future studies in complementary models and, ultimately, human trials confirm these coordinated effects, D-allulose could evolve from a niche sweetener into a genuine dietary tool against one of diabetes’ most overlooked complications.

Subject of Research: Effects of D-psicose (D-allulose) on hepatic steatosis, gut microbiota, and tryptophan-AhR signaling in a mouse model of type 2 diabetes

Article Title: D‐Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD/STZ‐Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR‐Related Signaling

Article References: Wu, L., Dong, X., Sun, W., Xu, H., Xie, Y., Liu, X., Liu, X., Ali, A., & Shao, K. (2026). D‐Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD / STZ ‐Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR ‐Related Signaling. Food Science & Nutrition, 14(10), Article e72455. https://doi.org/10.1002/fsn3.72455

Image Credits: AI Generated

DOI: 10.1002/fsn3.72455

Keywords: D-allulose, D-psicose, type 2 diabetes, fatty liver, MASLD, gut microbiota, tryptophan metabolism, aryl hydrocarbon receptor, NF-kappaB, intestinal barrier, Akkermansia, metabolomics

Cellular senescence is a state in which cells stop dividing permanently, usually in response to stress such as DNA damage, telomere shortening, or oxidative injury. Senescent cells are not simply dormant; they often develop what researchers call the senescence-associated secretory phenotype, a program in which they release a cocktail of inflammatory cytokines, growth factors, and enzymes that degrade the extracellular matrix. In many cancers, this secretory output is thought to create a pro-tumorigenic niche. Yet the precise contribution of senescent fibroblasts in ovarian cancer, and the identity of the molecules they use to communicate with tumor cells, had remained poorly defined. The new work set out to close that gap by combining large-scale genomic data with laboratory experiments and clinical samples.

The researchers began by mining publicly available single-cell RNA sequencing datasets, which measure gene expression in thousands of individual cells, alongside spatial transcriptomic data that preserve information about where cells sit within the tumor architecture. They also analyzed clinical specimens obtained from patients at Nanfang Hospital, with ethics approval and informed consent. By applying gene signatures associated with senescence to the fibroblast populations identified in these data, the team showed that cancer-associated fibroblasts in high-grade serous ovarian cancer carry a markedly elevated senescence program compared with other stromal and immune cell types in the same tumors. Spatial analysis placed these senescent fibroblasts in close proximity to malignant epithelial cells, hinting at a functional dialogue between the two compartments.

To translate that observation into something clinically useful, the team built a prognostic model based on the transcriptomic signature of the senescent fibroblasts. They used least absolute shrinkage and selection operator regression, a machine-learning technique that selects a compact set of predictive genes from a much larger candidate list, to derive a risk score for individual patients. When applied to cohort data, a high score on this senescent-fibroblast signature predicted significantly worse overall survival. The model therefore offers a way to stratify patients at diagnosis, potentially identifying those whose tumors are being nurtured by an aged stromal microenvironment and who might benefit from more aggressive or targeted treatment strategies.

The next question was mechanistic: which molecule, or molecules, do senescent fibroblasts use to promote tumor growth? Cell-cell communication analysis, a computational approach that matches ligands expressed by one cell type with receptors expressed by another, flagged Tenascin-C as a leading candidate. Tenascin-C is a large glycoprotein of the extracellular matrix that is abundant in embryonic tissues, largely absent from healthy adult tissue, and re-expressed in wounds and tumors. Among the genes in the prognostic signature, Tenascin-C stood out as a secreted effector produced by senescent fibroblasts and capable of signaling directly to tumor cells, making it an attractive linchpin for the observed pro-tumor effect.

Functional experiments in cell culture and in animal models confirmed the suspicion. When tumor cells were exposed to conditioned medium from senescent cancer-associated fibroblasts, they became more invasive and more migratory, hallmarks of malignant progression. Depleting or blocking Tenascin-C blunted these effects, demonstrating that the protein is a necessary mediator rather than a bystander. In vivo, the presence of senescent fibroblasts accelerated tumor growth in mouse models, and interference with the Tenascin-C axis reduced that acceleration. Together, these assays moved the finding from correlation to causation: the aged stromal cells promote ovarian cancer progression, and they do so substantially through Tenascin-C.

The study also resolved the signaling logic on both sides of the communication. On the receiving end, Tenascin-C engages syndecan-4, a transmembrane proteoglycan on the surface of tumor cells, which triggers the ERK mitogen-activated protein kinase pathway. ERK activation, in turn, drives epithelial-mesenchymal transition, a developmental program that cancer cells co-opt to lose their adhesive, epithelial character and acquire the motile, invasive traits of mesenchymal cells. Epithelial-mesenchymal transition is a well-established engine of metastasis and treatment resistance, so its induction explains how Tenascin-C exposure translates into poorer clinical outcomes. On the sending end, the researchers found that the nuclear factor kappa B pathway, a central inflammatory signaling cascade, is activated in the senescent fibroblasts and transcriptionally upregulates Tenascin-C expression, linking the senescence program itself to the production of the tumor-promoting factor.

To test how general the phenomenon might be, the team performed a pan-cancer analysis, examining the senescent-fibroblast risk score and Tenascin-C expression across multiple tumor types. The pattern held: high expression of Tenascin-C and a high senescent-fibroblast risk score were associated with worse overall survival across a range of solid tumors, not just ovarian cancer. This breadth suggests that the senescent stromal niche is not a peculiarity of high-grade serous ovarian cancer but a recurring feature of the tumor microenvironment, and that Tenascin-C may represent a broadly relevant node at which aged stroma communicates malignancy to neighboring epithelial cells.

The therapeutic implications are significant. High-grade serous ovarian cancer is typically diagnosed at an advanced stage and, despite initial responses to surgery and platinum-based chemotherapy, frequently recurs and eventually becomes resistant to treatment. Agents that target the tumor microenvironment rather than the tumor cells alone have shown promise in other contexts, and the identification of a single, druggable secreted mediator offers a concrete strategy. Blocking Tenascin-C, interrupting its binding to syndecan-4, or dampening the NF-kappaB-driven secretory program in senescent fibroblasts could, in principle, starve tumors of a key progression signal. Approaches that eliminate senescent cells altogether, so-called senolytics, represent another avenue suggested by this work, though the authors’ data point most directly at the Tenascin-C pathway itself.

As with any study, caveats apply. The prognostic model was developed and evaluated on existing datasets and clinical specimens, and prospective validation in independent patient cohorts will be needed before it can inform clinical decision-making. The mechanistic experiments, while thorough, were conducted in cell culture and animal models, and the complexity of the human tumor microenvironment, with its immune, vascular, and matrix components, may modulate the Tenascin-C pathway in ways not fully captured in the laboratory. Nevertheless, the study delivers an unusually complete chain of evidence, from single-cell atlas to survival statistics to signaling biochemistry, and it reframes cellular senescence in cancer not merely as a marker of an aged microenvironment but as an active, targetable driver of tumor progression. For patients with high-grade serous ovarian cancer, whose options narrow sharply at recurrence, a new molecular handle on the stromal side of the disease is a development worth watching closely.

Subject of Research: Senescent cancer-associated fibroblasts secreting Tenascin-C to promote tumor progression in high-grade serous ovarian cancer

Article Title: Senescent cancer-associated fibroblasts secrete Tenascin-C to promote tumor progression in high-grade serous ovarian cancer

Article References: Li, R., Chen, Y., Huang, X., Cai, J., Yang, Y., Fan, H., Xiang, Y., Meng, F., Huang, L., Li, Y., & Ning, Y. (2026). Senescent cancer-associated fibroblasts secrete Tenascin-C to promote tumor progression in high-grade serous ovarian cancer. Genome Medicine. https://doi.org/10.1186/s13073-026-01795-8

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01795-8

Keywords: ovarian cancer, cancer-associated fibroblasts, cellular senescence, Tenascin-C, tumor microenvironment, epithelial-mesenchymal transition, NF-kappaB, ERK signaling, single-cell RNA sequencing, prognostic model, high-grade serous ovarian cancer, senescence-associated secretory phenotype